Collegium Pharmaceutical (COLL) : During the past 4 weeks, traders have been relatively bearish on Collegium Pharmaceutical (COLL), hence the stock is down -17.95% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -12.26% relative to the S&P 500. The 4-week change in the price of the stock is -17.1% and the stock has fallen -12.21% in the past 1 week.
The stock has recorded a 20-day Moving Average of 12.5% and the 50-Day Moving Average is 20.06%. Collegium Pharmaceutical (NASDAQ:COLL): On Fridays trading session , Opening price of the stock was $10.51 with an intraday high of $10.75. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $9.35. However, the stock managed to close at $10.57, a loss of 0.75% for the day. On the previous day, the stock had closed at $10.65. The total traded volume of the day was 556,158 shares.
Institutional Investors own 61.53% of Collegium Pharmaceutical shares.
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Companys lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication. Xtampza has the same active ingredient as OxyContin OP, which is the abuse-deterrent, extended-release opioid in the United States. The Company has conducted a preclinical and clinical program for Xtampza on abuse-deterrence. These studies and clinical trials demonstrated that chewing, crushing and/or dissolving Xtampza, and then taking it orally or smoking, snorting or injecting it did not change its drug release profile.